126 related articles for article (PubMed ID: 9713956)
1. Single-chain immunotoxins targeted to CD40 for the treatment of human B-lineage hematologic malignancies.
Francisco JA; Siegall CB
Leuk Lymphoma; 1998 Jul; 30(3-4):237-45. PubMed ID: 9713956
[TBL] [Abstract][Full Text] [Related]
2. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
Francisco JA; Gilliland LK; Stebbins MR; Norris NA; Ledbetter JA; Siegall CB
Cancer Res; 1995 Jul; 55(14):3099-104. PubMed ID: 7541711
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40.
Francisco JA; Schreiber GJ; Comereski CR; Mezza LE; Warner GL; Davidson TJ; Ledbetter JA; Siegall CB
Blood; 1997 Jun; 89(12):4493-500. PubMed ID: 9192773
[TBL] [Abstract][Full Text] [Related]
4. Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1.
Francisco JA; Gawlak SL; Siegall CB
J Biol Chem; 1997 Sep; 272(39):24165-9. PubMed ID: 9305866
[TBL] [Abstract][Full Text] [Related]
5. Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin.
Francisco JA; Kiener PA; Moran-Davis P; Ledbetter JA; Siegall CB
J Immunol; 1996 Aug; 157(4):1652-8. PubMed ID: 8759752
[TBL] [Abstract][Full Text] [Related]
6. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells.
Uckun FM; Gajl-Peczalska K; Myers DE; Jaszcz W; Haissig S; Ledbetter JA
Blood; 1990 Dec; 76(12):2449-56. PubMed ID: 1702326
[TBL] [Abstract][Full Text] [Related]
7. Expression and characterization of bryodin 1 and a bryodin 1-based single-chain immunotoxin from tobacco cell culture.
Francisco JA; Gawlak SL; Miller M; Bathe J; Russell D; Chace D; Mixan B; Zhao L; Fell HP; Siegall CB
Bioconjug Chem; 1997; 8(5):708-13. PubMed ID: 9327135
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.
Chu YW; Polson A
Future Oncol; 2013 Mar; 9(3):355-68. PubMed ID: 23469971
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxins in the treatment of hematologic malignancies.
Kreitman RJ; Pastan I
Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
[TBL] [Abstract][Full Text] [Related]
10. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
Horton HM; Bernett MJ; Peipp M; Pong E; Karki S; Chu SY; Richards JO; Chen H; Repp R; Desjarlais JR; Zhukovsky EA
Blood; 2010 Oct; 116(16):3004-12. PubMed ID: 20616215
[TBL] [Abstract][Full Text] [Related]
11. The role of the CD40 antigen on malignant B cells.
Planken EV; Willemze R; Kluin-Nelemans JC
Leuk Lymphoma; 1996 Jul; 22(3-4):229-35. PubMed ID: 8819071
[TBL] [Abstract][Full Text] [Related]
12. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
Siegall CB
Recent Results Cancer Res; 1996; 140():51-60. PubMed ID: 8787077
[No Abstract] [Full Text] [Related]
13. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Multani PS; O'Day S; Nadler LM; Grossbard ML
Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
[TBL] [Abstract][Full Text] [Related]
14. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
15. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
[TBL] [Abstract][Full Text] [Related]
16. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
18. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P
Leuk Lymphoma; 1994 May; 13(5-6):441-8. PubMed ID: 8069189
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
